Can HBsAg Be Used as a Viral Replication Marker in Chronic Hepatitis B Patients?

Journal Title: Viral Hepatitis Journal - Year 2017, Vol 23, Issue 2

Abstract

Objective: Monitoring hepatitis B virus (HBV) treatment responses and virus replication is performed with molecular tests. However, these tests are either expensive or invasive. A new and more practical marker is needed. We aimed to evaluate the correlation between serum hepatitis B surface antigen (HBsAg) and alanine aminotransferase (ALT) levels and HBV DNA level in hepatitis B e antigen (HBeAg) +/- patients and detect whether HBsAg can be used as a surrogate replication marker instead of HBV DNA. Material and Methods: A retrospective study was conducted in 59 chronic hepatitis B patients. Serum ALT, HBsAg and HBeAg levels and HBV DNA levels were recorded. The results were analysed with the Mann-Whitney U test and Spearman correlation coefficient. A p value of ≤0.05 was considered statistically significant. Sequential results were compared using Blant-Alpman plot. Results: The patients were grouped as HBeAg-positive (37.2%) and HBeAg-negative (62.8%). Serum ALT levels were elevated in 82% of HBeAg-positive and 70.2% of HBeAg-negative subjects. There was a statistically significant difference in HBsAg levels between the groups (p<0.05). However, there was no statistically significant difference in ALT and HBV DNA levels (p>0.05). A statistically significant negative correlation was detected between HBsAg and HBV DNA levels in HBeAg-positive patients. No correlation was found between HBsAg and HBV DNA levels in HBeAg-negative subjects (p<0.05). In both HBeAg-positive and -negative individuals, there was a positive correlation between serum ALT and HBV DNA levels (p<0.05). Blant-Alpman graph did not show an appropriate profile. Conclusion: We found a negative correlation between HBsAg and HBV DNA levels in HBeAg-positive patients. However, this correlation is not practical in monitoring treatment response and replication.

Authors and Affiliations

Emel UZUNOĞLU, Ahmet Melih ŞAHİN, Esin AVCI, Hakan KUTLU, Gökçe Gökçe GÜNTEPE

Keywords

Related Articles

Direct-acting Antiviral Therapy for Mixed Genotype Chronic Hepatitis C Infection

Objectives: Literature data concerning the outcomes of direct acting antiviral (DAA) therapy in mixed genotype hepatitis C virus (HCV) infections are very limited, and the incidence of mixed HCV infection in Turkey is un...

A Misleading Parameter in the Diagnosis of Chronic Hepatitis B: Persistently Normal Transaminases

Objectives: Most of the patients with hepatitis B e (HBe)-negative hepatitis B have persistently normal transaminases (PNALT) levels. Patients, who have higher fibrosis and necroinflammatory activity scores, are at high...

Immunosuppressive Therapy and Hepatitis B Virus Reactivation

Reactivation of hepatitis B virus (HBV) refers to reappearance of active necroinflammatory disease of the liver in an individual at an inactive hepatitis B surface antigen carrier state or who is known to have resolved H...

Failure of Direct-Acting Antiviral Agents Due to Incomplete Hepatitis C Virus Genotyping

Current direct-acting antivirals (DAAs) have high success rates in the treatment of chronic hepatitis C virus (HCV) infection. However, 1-15% of patients fail to achieve viral eradication. Some factors may play a role in...

Circulating Glucose-Regulated Protein 78 Levels in Patients with Chronic Hepatitis B Infection

Objectives: The role of endoplasmic reticulum (ER) stress in the pathogenesis of hepatitis B virus (HBV) has been reported. However, serum levels of glucose-regulated protein (GRP) 78 which is an ER stress marker both in...

Download PDF file
  • EP ID EP251836
  • DOI 10.4274/vhd.73645
  • Views 42
  • Downloads 0

How To Cite

Emel UZUNOĞLU, Ahmet Melih ŞAHİN, Esin AVCI, Hakan KUTLU, Gökçe Gökçe GÜNTEPE (2017). Can HBsAg Be Used as a Viral Replication Marker in Chronic Hepatitis B Patients?. Viral Hepatitis Journal, 23(2), 55-59. https://europub.co.uk/articles/-A-251836